One million patients had undergone FUS therapy since the technology was introduced six decades ago, including around 175,000 cases that involved liver tumours, according to data compiled by the Focused Ultrasound Foundation in Charlottesville, Virginia.
The increasing adoption is accompanied by wider application, where the number of diseases being treated or under research has risen to more than 200 from three over the past decade, the foundation said. The number of companies making the devices for FUS has surged to 77 from five, 34 of them based in North America, 22 in Asia and 16 in Europe.
The trend is good news for companies like HistoSonics in Minnesota state, a producer of FUS devices for treating liver tumours, which sold a 70 per cent stake in August to a group of investors including the Bezos Expedition and Wellington Management, making the start-up a so-called unicorn with a US$2.25 billion valuation.
“By next year, I expect one or more ‘north star’ companies – those that have over US$100 million in annual revenues and are profitable – to emerge,” said Kassell during an interview with the Post in Hong Kong. “They will be ready to either go public or be sold to major strategic investors like multinational medical device makers.”
